1204249-43-3

Upstream product

• 91-13-4 α,α'-dibromo-o-xylene 
• 168893-82-1 diphenyl cyanocarbonimidate 
• 740842-50-6 2-nitro-8,9-dihydro-5H-benzo[7]annulene-7(6H)-one 
• 37949-03-4 5,6,8,9-tetrahydrobenzo[7]annulen-7-one 
• 24790-66-7 dimethyl 1,2,4,5-tetrahydro-3-oxobenzocycloheptene-2,4-dicarboxylate 
• 79463-77-7 N-cyanodiphenylcarbonimidate 

Downstream Products

• 1204249-46-6 (7S)-1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N₃-(7-(t-butoxycarbonylamino)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine 

Relevant academic research and scientific papers

AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER

This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective

POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases

BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Bridged bicyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase AxI. Methods of using the compounds in treating diseases or conditions associated with AxI activity are also disclosed